molecules of the month

Cerevel/Pfizer M4 positive allosteric modulator

oral, QD M4 PAM

Ph. II for schizophrenia

discovery not disclosed

emraclidine (CVL-231)

Cerevel Therapeutics, Cambridge, MA; Pfizer, New York, NY

1 min read

Emraclidine (CVL-231) is a selective positive allosteric modulator (PAM) of the cholinergic M4 muscarinic receptor and is the only selective M4 PAM in clinical development. The molecule has shown promising early results in schizophrenia with several Ph. II trials enrolling and is intended to be developed for Alzheimer’s Disease psychosis as well. The molecule is highly brain penetrant and has shown clear target engagement based on PET studies in non-human primates. The role of M4 in treating psychosis has validation from clinical studies from the ‘90s with M1/M4 agonist xanomeline, which was not further developed due to side effects. With its >390x selectivity for M4 over other muscarinic receptors and more moderate positive allosteric modulator mechanism vs. full agonism, emraclidine…

request a trial

Drug Hunter is commited to helping industry innovators make informed decisions. Premium members have access to our library of the latest stories in science, written by scientists.

Request a trial to access insights powering the pros in our industry.

already a member? log in: